Know Cancer

forgot password

A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies

Phase 1
18 Years
Open (Enrolling)
Cancer, Solid Tumor

Thank you

Trial Information

A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies

CALAA-01 is a targeted nanocomplex that contains anti-R2 siRNA. The complete nanocomplex
formulation consists of four components:

1. a duplex of synthetic, non-chemically-modified siRNA (C05C)

2. a cyclodextrin-containing polymer (CAL101),

3. a stabilizing agent (AD-PEG), and

4. a targeting agent (AD-PEG-Tf) that contains the human transferrin protein (Tf). The
cationic polymer interacts electrostatically with anionic siRNA to assemble into
nanocomplexes below approximately 100 nm in diameter that protect the siRNA from
nuclease degradation in serum. The siRNA-containing nanocomplexes are targeted to cells
that over express the transferrin receptor (TfR). Upon reaching a target cell,
transferrin binds to TfRs on the cell surface and the siRNA-containing nanocomplex
enters the cell by endocytosis. Inside the cell, chemistry built into the polymer
achieves unpackaging of the siRNA from the nanocomplex, permitting it to function via
RNA interference.

Inclusion Criteria

Inclusion Criteria include:

- Subjects must be at least eighteen (18) years of age.

- Subjects must have the following:

- Histologically- or cytologically-confirmed solid malignancy that is measurable
or non-measurable recurrent or metastatic disease (i.e., evaluable; e.g.,
cytologically or radiologically-detectable disease, markers, etc.)

- Measurable disease is metastatic or unresectable

- Standard curative or palliative measures do not exist, are no longer effective,
or are unlikely to be effective.

- Subjects must have tumors that have recurred after previous surgery and/or radiation.

- Subjects must have received prior adjuvant, neoadjuvant, or any other therapy for
metastatic disease. No restriction is placed on the number of cycles or regimens of
prior therapy.

- Subjects must have fully recovered from diagnostic or therapeutic surgery (i.e.,
complete wound healing).

- Subjects must have fully recovered from prior radiotherapy for local symptom

- Subjects must have recovered from the toxic effects of prior therapy.

- Women and men of child-bearing/conceiving potential must be willing to use highly
effective contraceptive methods during the course of the study. Any female who is not
sexually active must agree to begin using highly effective contraceptive methods if
she becomes sexually active during the study. Females who are post-menopausal (i.e.,
no longer menstruating) must have been so for two (2) years.

- Females of child-bearing potential (e.g., not surgically sterilized or two (2) years
post-menopausal) must have a negative urine pregnancy test at screening. Positive
tests will be confirmed serologically.

- Subjects must have adequate marrow, hepatic, and renal function at the time of

- Subjects must be willing and able, in the opinion of the Investigator, to comply with
the protocol tests and procedures.

- Subjects must be willing and able to give written informed consent.

Exclusion Criteria include:

- Pregnant or nursing females.

- Clinically-evident (e.g., abdominal distention, bulging and/or fluid wave) ascites or
Grade 3 peripheral edema.

- Allergy(ies) to contrast media required for protocol testing.

- History of significant weight loss within four (4) weeks prior to baseline.

- Evidence of active, uncontrolled infection or unstable or severe intercurrent medical

- Peripheral venous access insufficient to permit infusion of intravenous CALAA-01 and
acquisition of laboratory specimens.

- Alcoholism (dependency), alcohol or substance abuse within twelve (12) months prior
to screening that has caused health consequences.

- Immunocompromised subjects, subjects with known autoimmune conditions, active
hepatitis or human immunodeficiency virus (HIV) seropositivity.

- Prior gene transfer therapy or prior therapy with a cytolytic virus of any type.

- Any electrocardiogram (ECG) abnormality at screening documented by the Principal
Investigator as clinically significant.

- Vaccinations of any kind within thirty (30) days of baseline.

- Use of any investigational agent or device within thirty (30) days of CALAA-01

- Any concomitant medical or psychiatric condition or social situation that would make
it difficult to comply with protocol requirements.

- Subjects requiring anticonvulsants.

- Radiotherapy, cytotoxic chemotherapy, biologic, hormonal or immunotherapy or bone
marrow transplantation within four (4) weeks of baseline; nitroureas within six (6)
weeks. Current use of growth factors.

- A myocardial infarction within six (6) months prior to enrollment or having New York
Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina,
cardiomyopathy, severe uncontrolled ventricular arrhythmias, left bundle branch
block, or electrocardiographic evidence of acute ischemic or active conduction system
abnormalities (e.g., Long QT interval, Torsade de Pointes).

- Poorly controlled hypertension

- Prior corticosteroids as anticancer therapy within seven (7) days of baseline.

- Active CNS metastases or currently receiving dexamethasone for CNS disease.

- Major surgery within four (4) weeks of baseline.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the tolerability, safety profile and maximum tolerated dose (MTD) of intravenous CALAA-01.

Outcome Time Frame:

3 months

Safety Issue:


Principal Investigator

Antoni Ribas, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

UCLA Jonsson Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

May 2008

Completion Date:

December 2012

Related Keywords:

  • Cancer
  • Solid Tumor
  • siRNA
  • RNA interference (RNAi)
  • Cyclodextrin
  • Cancer
  • Neoplasms
  • Solid Tumor
  • Ovarian Cancer
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Colon Cancer
  • Endometrial Cancer
  • Kidney (Renal Cell) Cancer
  • Melanoma
  • Prostate Cancer
  • Skin Cancer
  • Thyroid Cancer
  • Solid Malignancies
  • Neoplasms



City of Hope National Medical Center Los Angeles, California  91010
UCLA Jonsson Comprehensive Cancer Center Los Angeles, California  90095
START (South Texas Accelerated Research Therapeutics) San Antonio, Texas  78229